                         SEQUENCE LISTING

<110>  MAB Explorations Sdn Bhd
 
<120>  ANTIBODIES SPECIFIC FOR ENTEROVIRUSES THAT INFECT HUMANS

<130>  FP7176

<150>  MY PI 2013004513
<151>  2013-12-16

<160>  30    

<170>  PatentIn version 3.5

<210>  1
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E18 VL Chain

<400>  1

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Lys Ser Tyr 
            20                  25                  30          


Leu Ser Trp Tyr Gln Gln Lys Pro Trp Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Lys Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Phe Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  


Asp Asp Thr Ala Thr Tyr Tyr Cys Leu Gln His Gly Glu Ser Pro Tyr 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  2
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E18 VH Chain

<400>  2

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Ser Asn Tyr Tyr Pro Met Asp Phe Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  3
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 VL Chain

<400>  3

Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 
1               5                   10                  15      


Gly Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys His Gln 
                85                  90                  95      


Tyr Leu Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  4
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 VH1 Chain

<400>  4

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Gln Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Ala Glu Thr Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Asp Gly Gly Ser His Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ala Leu Tyr 
65                  70                  75                  80  


Leu Glu Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Gly Arg Arg Ala Gly Arg Tyr Asp Glu Arg Asp Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  5
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 VH2 Chain

<400>  5

Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser 
1               5                   10                  15      


Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser 
            20                  25                  30          


Gly Phe Tyr Leu Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu 
        35                  40                  45              


Trp Met Gly Tyr Ile Asn Tyr Gly Gly Ser Ile Asn Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Phe Leu Arg Leu Asn Ser Val Thr Ala Glu Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Thr Met Pro Asn Ser Trp Tyr Phe Asp Val Trp Gly Thr Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  6
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E20 VL Chain

<400>  6

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Pro Val Ser Ala Gly 
1               5                   10                  15      


Asp Arg Val Thr Met Thr Cys Lys Ala Ser Gln Ser Val Gly Asn Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Val 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln His Tyr Ser Ser Pro Pro 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  7
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E20 VH Chain

<400>  7

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Asn Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser His Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Val Arg Asp Arg Gly Asn Tyr Tyr Ser Arg Ala Phe Pro Tyr Ala Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
        115                 120             


<210>  8
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E18 VL Chain

<400>  8
gacatcaaga tgacccagtc tccatcctcc atgtatgcat cgctgggaga gagagtcact       60

atcacttgca aggcgagtca ggacattaaa agctatttaa gctggtacca gcagaaacca      120

tggaaatctc ctaagaccct gatctattat gcaaaaaact tggcagatgg ggtcccatca      180

agattcagtg gcagtggatt tgggcaagat tattctctaa ccatcagcag cctggagtct      240

gacgatacag caacttatta ctgtctacag catggtgaga gcccgtatac gttcggatcg      300

gggaccaaac tggaaataaa acgg                                             324


<210>  9
<211>  360
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E18 VH Chain

<400>  9
cagatccagt tggtacagtc tggacctgag ctgaagaagc ctggagagac agtcaagatc       60

tcctgcaagg cttctggata taccttcaca aggtatggaa tgagctgggt gaaacaggct      120

ccaggaaagg gtttaaagtg gatgggctgg ataaacacct actctggagt gccaacatat      180

gctgacgact tcaagggacg gtttgccttc tctttggaaa cctctgccag cactgcctat      240

ttgcagatca acaacctcaa aaatgaggac acggctacat atttctgtgc aagaaggggg      300

tatagtaact attatcctat ggacttctgg ggtcaaggaa cctcagtcac cgtctcctca      360


<210>  10
<211>  336
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 VL Chain

<400>  10
aacattatga tgacacagtc gccatcatct ctggctgtgt ctgcaggagg aaaggtcact       60

atgagctgta agtccagtca aagtgtttta tacagttcaa atcagaagaa ctacttggcc      120

tggtaccagc agaaaccagg gcagtctcct aaactactga tctactgggc atccactagg      180

gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacagattt tactcttacc      240

atcagcagtg tacaagctga agacctggca gtttattact gtcatcaata cctctcctcg      300

tggacgttcg gtggaggcac caagctggaa atcaaa                                336


<210>  11
<211>  366
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 VH1 Chain

<400>  11
gaagtgatgc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctccaactc       60

tcctgtgcag cctctggatt cacgttcagt gactatgcca tgtcttgggt tcgccagact      120

gcggagacga ggctggagtg ggtcgcaacc atcagtgatg gtggtagtca cacctactat      180

ccagacagtg tgaggggacg gttcaccatc tccagagaca atgccaagaa ggccctgtac      240

ctggaaatga gcagtctgaa gtctgaggac acggccatgt attactgtgg aagacgggcg      300

gggaggtacg atgagagaga tgctatggac tactggggtc aaggaaccac agtcaccgtc      360

tcctca                                                                 366


<210>  12
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 VH2 Chain

<400>  12
tctgatgtac agcttcagga gtcaggacct ggcctcgtga aaccttctca gtctctgtct       60

ctcacctgct ctgtcactgg ctactccatc accagtggtt tttacttaaa ctggatccgg      120

cagtttccag gaaacaaact ggaatggatg ggctacataa actacggtgg tagcattaac      180

tacaacccat ctctcaaaag tcgcatctcc atcactcgtg acacatctaa gaaccagttt      240

ttcctgaggt tgaattctgt gactgctgag gacacagcca catattactg tgcaaccatg      300

cctaactcct ggtacttcga tgtctggggc acagggacca cggtcaccgt ctcctca         357


<210>  13
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E20 VL Chain

<400>  13
agtattgtga tgacccagac tcccaaattc ctgcctgtat cagcaggaga cagggttacc       60

atgacctgca aggccagtca gagtgtgggt aataatgtag cctggtacca acagaagtca      120

ggacagtctc ctaaactgct gatatactat gcatccaatc gctacactgg agtccctgat      180

cgcttcactg gcagtggatc tgggacagat ttcactttca ccatcagcag tgtgcaggtt      240

gaagacctgg cagtttattt ctgtcagcag cattatagct ctcctcccac gttcggtgct      300

gggaccaagc tggagctgaa a                                                321


<210>  14
<211>  369
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E20 VH Chain

<400>  14
gaagtgcagc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc       60

tcctgtgcag cctctggatt cactttcaac atctatgcca tgtcttgggt tcgccagact      120

ccggaaaaga ggctggagtg ggtcgcaacc attagtgatg gtggtagtta tacctactat      180

ccagacaatg taaagggccg attcaccatc tccagagaca atgccaagaa caacctgtac      240

ctgcaaatga gccatctgaa gtctgaggac acagccatgt attactgtgt aagagatcga      300

ggaaattact acagtagagc gttcccgtat gcttactggg gccaagggac tctggtcact      360

gtctctgca                                                              369


<210>  15
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E18 VL2 Chain derived from SEQ ID NO: 1

<400>  15

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Lys Ser Tyr 
            20                  25                  30          


Leu Ser Trp Tyr Gln Gln Lys Pro Trp Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Lys Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Phe Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  


Asp Asp Thr Ala Thr Tyr Tyr Cys Leu Gln His Gly Glu Ser Pro Tyr 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  16
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VL1 Chain derived from SEQ ID NO: 3


<400>  16

Asn Ile Met Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln 
                85                  90                  95      


Tyr Leu Ser Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  17
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VL2 Chain derived from SEQ ID NO: 3

<400>  17

Asn Ile Met Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln 
                85                  90                  95      


Tyr Leu Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  18
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VL3 Chain derived from SEQ ID NO: 3

<400>  18

Asn Ile Met Met Thr Gln Ser Pro Asp Ser Leu Ala Leu Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 
            20                  25                  30          


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Leu Tyr Tyr Cys His Gln 
                85                  90                  95      


Tyr Leu Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  19
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH1 Chain derived from SEQ ID NO: 5

<400>  19

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Gly 
            20                  25                  30          


Phe Tyr Leu Asn Trp Ile Arg Gln His Pro Cys Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Asn Tyr Gly Gly Ser Ile Asn Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Met Pro Asn Ser Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  20
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH2 Chain derived from SEQ ID NO: 5

<400>  20

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Gly 
            20                  25                  30          


Phe Tyr Leu Asn Trp Ile Arg Gln His Pro Gly Lys Lys Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Asn Tyr Gly Gly Ser Ile Asn Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Met Pro Asn Ser Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  21
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH3 Chain derived from SEQ ID NO: 5

<400>  21

Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Gly 
            20                  25                  30          


Phe Tyr Leu Asn Trp Val Arg Gln His Pro Gly Lys Lys Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Asn Tyr Gly Gly Ser Ile Asn Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Met Pro Asn Ser Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  22
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH4 Chain derived from SEQ ID NO: 20

<400>  22

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Gly 
            20                  25                  30          


Phe Tyr Leu Asn Trp Ile Arg Gln His Pro Gly Lys Lys Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Asn Tyr Gly Gly Ser Ile Asn Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Met Pro Asn Ser Trp Tyr Phe Asp Val Trp Gly Thr Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  23
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E18 VL2 Chain derived from SEQ ID NO: 1

<400>  23
gacatcaaga tgacccagtc tccatcctcc atgtatgcat cgctgggaga gagagtcact       60

atcacttgca aggcgagtca ggacattaaa agctatttaa gctggtacca gcagaaacca      120

tggaaatctc ctaagaccct gatctattat gcaaaaaact tggcagatgg ggtcccatca      180

agattcagtg gcagtggatt tgggcaagat tattctctaa ccatcagcag cctggagtct      240

gacgatacag caacttatta ctgtctacag catggtgaga gcccgtatac gttcggatcg      300

gggaccaaac tggaaataaa a                                                321


<210>  24
<211>  336
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VL1 Chain derived from SEQ ID NO: 3

<400>  24
aatatcatga tgacccagtc ccccgactcc ctggccgtgt ctctgggaga gagagccacc       60

atcaactgca agtcctccca gtccgtgctg tactcctcca accagaagaa ctacctggcc      120

tggtatcagc agaagcccgg ccagcctccc aagctgctga tctactgggc ctccacccgg      180

gaatctggcg tgcccgatag attctccggc tccggctctg gcaccgactt taccctgacc      240

atcagctccc tgcaggccga ggatgtggcc gtgtactact gccaccagta cctgtcctct      300

tggaccttcg gccagggcac caaggtggaa atcaag                                336


<210>  25
<211>  336
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VL2 Chain derived from SEQ ID NO: 3

<400>  25
aatatcatga tgacccagtc ccccgactcc ctggccgtgt ctctgggaga gagagccacc       60

atcaactgca agtcctccca gtccgtgctg tactcctcca accagaagaa ctacctggcc      120

tggtatcagc agaagcccgg ccagtcccct aagctgctga tctactgggc ctccacccgg      180

gaatctggcg tgcccgatag attctccggc tccggctctg gcaccgactt taccctgacc      240

atcagctccc tgcaggccga ggatgtggcc gtgtactact gccaccagta cctgtcctct      300

tggaccttcg gcggaggcac caaggtggaa atcaag                                336


<210>  26
<211>  336
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VL3 Chain derived from SEQ ID NO: 3

<400>  26
aatatcatga tgacccagtc ccccgactcc ctggccctgt ctctgggaga gagagccacc       60

atcaactgca agtcctccca gtccgtgctg tactcctcca accagaagaa ctacctggcc      120

tggtatcagc agaagcccgg ccagtcccct aagctgctga tctactgggc ctcctcccgg      180

gaatctggcg tgcccgatag attctccggc tccggctctg gcaccgactt taccctgacc      240

atcagctccc tgcaggccga ggatgtggcc ctgtactact gccaccagta cctgtcctct      300

tggaccttcg gcggaggcac caaggtggaa atcaag                                336


<210>  27
<211>  354
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH1 Chain derived from SEQ ID NO: 5

<400>  27
gatgtgcagc tgcaggaatc tggccctggc ctcgtgaagc cttcccagac cctgtctctg       60

acctgcaccg tgtccggcta ctccatcacc tccggcttct acctgaactg gatccggcag      120

cacccctgca agggcctgga atggatcggc tacatcaact acggcggctc tatcaactac      180

aaccccagcc tgaagtccag agtgaccatc tcccgggaca cctccaagaa ccagttctcc      240

ctgaagctgt cctccgtgac cgccgctgat accgccgtgt actactgcgc taccatgccc      300

aacagctggt acttcgacgt gtggggcaga ggcaccctcg tgaccgtgtc atct            354


<210>  28
<211>  354
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH2 Chain derived from SEQ ID NO: 5

<400>  28
gatgtgcagc tgcaggaatc tggccctggc ctcgtgaagc cttcccagac cctgtctctg       60

acctgcaccg tgtccggcta ctccatcacc tccggcttct acctgaactg gatccggcag      120

caccccggca agaaactgga atggatcggc tacatcaact acggcggctc tatcaactac      180

aaccccagcc tgaagtccag agtgaccatc tcccgggaca cctccaagaa ccagttctcc      240

ctgaagctgt cctccgtgac cgccgctgat accgccgtgt actactgcgc taccatgccc      300

aacagctggt acttcgacgt gtggggcacc ggcaccctcg tgacagtgtc atct            354


<210>  29
<211>  354
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH3 Chain derived from SEQ ID NO: 5

<400>  29
gaagtgcagc tggtggaatc tggccctggc ctcgtgaagc cttcccagac cctgtctctg       60

acctgcaccg tgtccggcta ctccatcacc tccggcttct acctgaactg ggtgcgacag      120

caccccggca agaaactgga atggatcggc tacatcaact acggcggctc tatcaactac      180

aaccccagcc tgaagtcccg ggtgtccatc tcccgggaca cctccaagaa ccagttctcc      240

ctgaagctga cctccgtgac cgccgctgat accgccgtgt actactgcgc taccatgccc      300

aacagctggt acttcgacgt gtggggcacc ggcaccctcg tgacagtgtc atct            354


<210>  30
<211>  357
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody E19 humanized VH4 Chain derived from SEQ ID NO: 20

<400>  30
gatgtgcagc tgcaggaatc tggccctggc ctcgtgaagc cttcccagac cctgtctctg       60

acctgcaccg tgtccggcta ctccatcacc tccggcttct acctgaactg gatccggcag      120

caccccggca agaaactgga atggatcggc tacatcaact acggcggctc tatcaactac      180

aaccccagcc tgaagtccag agtgaccatc tcccgggaca cctccaagaa ccagttctcc      240

ctgaagctgt cctccgtgac cgccgctgat accgccgtgt actactgcgc tcgcaccatg      300

cccaacagct ggtacttcga cgtgtggggc accggcaccc tcgtgacagt gtcatct         357


